Filing Flows › Theravance Biopharma (TBPH) › Q2 2025
Theravance Biopharma (TBPH) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 13, 2025
Theravance Biopharma (TBPH) reported revenue of $26.2M for the second quarter 2025 (Q2 2025), +84% from a year earlier and +70% from the quarter before. Operating margin was -10.4%, net earnings $54.8M (209.3% of revenue).
Theravance Biopharma, Q2 2025: revenue $26.2M (+84% year over year), operating margin -10.4%, net earnings $54.8M, operating cash flow $208M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $26.2M | +70% | +84% |
| Operating profit | −$2.7M | — | — |
| Net earnings | $54.8M | — | — |
| Operating cash flow | $208M | +383% | — |
What changed
Revenue was $26.2M in Q2 2025, up 84% year over year and up 70% from the previous quarter. Viatris collaboration agreement was the largest line at 71% of revenue. Viatris collaboration agreement added $4.4M year over year (up 31%), 37% of the total change.
Operating costs exceeded revenue by $2.7M, an operating margin of -10.4%. Total costs fell 3% while revenue rose 84%. Net earnings were $54.8M. The effective tax rate was 25.1%. Non-operating items added $75.9M, 104% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $208.1M, 379% of net earnings. Non-cash charges added back $4.5M of share-based compensation. Working capital and other items added $148.7M.
Questions
What was Theravance Biopharma's revenue in the second quarter 2025?
Theravance Biopharma (TBPH) reported revenue of $26.2M for the second quarter 2025 (Q2 2025), +84% from a year earlier and +70% from the quarter before.
Was Theravance Biopharma profitable in the second quarter 2025?
Operating loss was $2.7M (-10.4% of revenue) and net earnings $54.8M.